<DOC>
	<DOC>NCT00920907</DOC>
	<brief_summary>The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes</brief_summary>
	<brief_title>Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologic diagnosis of malignant melanoma Eastern Cooperative Oncology Group (ECOG) performance status 01 Measurable/evaluable disease per modified World Health Organization (mWHO) criteria Active Brain Metastasis Primary ocular or mucosal melanoma Prior Autoimmune disease Inadequate hematologic, hepatic or renal function Use of immunosuppressants Prior treatment with a CD137 agonist or cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>